Literature DB >> 1285918

Clinicopathologic and immunophenotypic study of non-Hodgkin's lymphoma in Korea. Lymphoreticular Study Group of the Korean Society of Pathologists.

C W Kim1, I Kim, Y H Ko, H Cho, W I Yang, G Y Kwon, D G Lee, H B Moon, C H Suh, S W Juhng.   

Abstract

This study sponsored by the Lymphoreticular Study Group of the Korean Society of Pathologists was carried out to provide nationwide data about the histopathologic-immunophenotypic features of malignant lymphomas in Korea. Two hundred and ninety Non-Hodgkin's lymphoma (NHL) among 312 malignant lymphomas collected from three representative areas in Korea were histologically reclassified. Two hundred and fifty three cases were immunohistochemically studied. T-cell lymphoma comprised 35.2% of NHL in this study and showed a quite comparable incidence to that of Japan and China, but it was much higher than in Western countries. A very low prevalence rate of the follicular variety (4.0%) and a higher propensity of primary extranodal involvement (60%) are additional characteristics of NHL in Korea. The most common histologic subtype of B cell lymphoma was diffuse large cell type, whereas the most common subtype of T cell lymphoma was diffuse mixed small and large cell type.

Entities:  

Mesh:

Year:  1992        PMID: 1285918      PMCID: PMC3053778          DOI: 10.3346/jkms.1992.7.3.193

Source DB:  PubMed          Journal:  J Korean Med Sci        ISSN: 1011-8934            Impact factor:   2.153


  2 in total

1.  Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph).

Authors:  Lindsay M Morton; Jennifer J Turner; James R Cerhan; Martha S Linet; Patrick A Treseler; Christina A Clarke; Andrew Jack; Wendy Cozen; Marc Maynadié; John J Spinelli; Adele Seniori Costantini; Thomas Rüdiger; Aldo Scarpa; Tongzhang Zheng; Dennis D Weisenburger
Journal:  Blood       Date:  2007-03-27       Impact factor: 22.113

2.  Addition of rituximab to the CHOP regimen has no benefit in patients with primary extranodal diffuse large B-cell lymphoma.

Authors:  Geundoo Jang; Dok Hyun Yoon; Shin Kim; Dae Ho Lee; Sang-Wook Lee; Jooryung Huh; Cheolwon Suh
Journal:  Korean J Hematol       Date:  2011-06-21
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.